Nayan Ghosh, Ph.D.
Sr Scientist,Division Of Medicinal and Process Chemistry
Green synthetic approaches for biologically relevant Heterocycles
Group web page:
https://sites.google.com/view/nayancdri/home
➤Development of novel organic reaction for the synthesis of fused-hetero/carbocycle viacascadecyclization pathway.
➤Target-oriented synthesis of small bioactive molecule.
➤Synthesis of novel hypervalent iodine derivatives and exploring their use in the area of organo catalysis and medicinal field.
➤Development of synthetic methodology useful for biological and drug discovery researches based on organic chemistry.
Aryne Chemistry
Arynes are one of the mostreactive intermediate in organic chemistry offering numerous applications in organic synthesis. Presence of strained bond in the ring makes aryne highly reactive. In a one pot operation, in situ generated aryne has been employed for the rapid construction of molecular complexity and diversity through the formation of multiple C−C and C−heteroatom bonds in a selective manner. Even though a numerous reactions on aryne chemistry have been appeared in the literature, alpplication of aryne chemistry for making natural product and the synthesis of scaffold of biological relevance remains elusive.Therefore, our research group’s primary focus will be to find novel organictransformation, total synthesis of natural product, and synthesis of small drug like molecule employing reactive aryne intermediate.
Tuberculosis Research
Tuberculosis (TB), one of the world’s major causes of illness and death, is an infectious disease caused by Mycobacterium tuberculosis (MTB). According to World Health Organisation estimation (WHO), approximately death of 1.4 million people was reported worldwide in 2015. The spread of multidrug-resistant (MDR) TB and the emergence of extensively drug-resistant (XDR) TB have been accelerated drug discovery effort in search of novel drug. Although Bedaquiline and Delamanid were approved for the treatment of MDR-TD over a huge gap of over 40 years, both of them have pronounced issues of toxicity.Therefore, there is an urgent need to develop new anti-TB drugs to stop the spread of the disease.Hence, the role of our research group would be to improve the synthetic efficiency of APIs of existing drugs and synthesis of active APIs for tuberculosis treatment.
